Defence Therapeutics

(OTC) DTCFF

Current Price$0.39

Market Cap$29.56M

Since IPO (2021)-84%

5 Year-84%

1 Year-28%

1 Month+12%

Defence Therapeutics Financials at a Glance

Market Cap

$29.56M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$6.19M

EPS (TTM)

-$0.08

P/E Ratio

-4.82

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$0.39

Volume

6,500

Open

$0.37

Price

$0.39

Volume

6,500

Open

$0.37

Previous Close

$0.39

Daily Range

$0.35 - $0.39

52-Week Range

$0.31 - $0.78

Estimated Earnings Date

Jun 21, 2022

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$0.39

Volume

6,500

Open

$0.37

Previous Close

$0.39

Daily Range

$0.35 - $0.39

52-Week Range

$0.31 - $0.78

Estimated Earnings Date

Jun 21, 2022

DTCFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Defence Therapeutics

Industry

Biotechnology

Sector

Health Care

CEO

Sébastien Plouffe

Website

www.defencetherapeutics.com

Headquarters

Vancouver, BC V6C 3L6, CA

DTCFF Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-247%

Return on Capital

-54%

Return on Assets

-67%

Earnings Yield

-20.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$29.56M

Shares Outstanding

75.79M

Volume

6.50K

Avg. Volume

4.85K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$3.00M

EBITDA

-CA$2.93M

Operating Cash Flow

-CA$3.00M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$3.00M

Cash & ST Invst.

CA$1.23M

Total Debt

CA$1.51M

Defence Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$9.45K

N/A

Gross Margin

0.00%

N/A

Market Cap

$29.56M

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-CA$2.97M

-211.9%

EBITDA

-CA$1.41M

-65.7%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Total Cash

CA$2.96M

+42.4%

Total Debt

CA$1.57M

+12.6%

Accounts Receivable

CA$316.00K

+259.9%

Inventory

CA$0.00

N/A

Long Term Debt

CA$1.57M

N/A

Short Term Debt

CA$0.00

-100.0%

Return on Assets

-67.17%

N/A

Return on Invested Capital

-53.54%

N/A

Free Cash Flow

-CA$1.59M

+20.2%

Operating Cash Flow

-CA$1.59M

+20.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MBXBFMicrobix Biosystems Inc.

MBXBFMicrobix Biosystems Inc.$0.19+0.00%

PVCTProvectus Biopharmaceuticals, Inc.

PVCTProvectus Biopharmaceuticals, Inc.$0.06-10.29%

SEOVFSernova Corp.

SEOVFSernova Corp.$0.11+0.00%

CLYYFCelyad Oncology S.A.

CLYYFCelyad Oncology S.A.$0.25+0.00%

MMIRFMedMira Inc.

MMIRFMedMira Inc.$0.01+0.00%

WOWUWOWI, Inc.

WOWUWOWI, Inc.$0.00+0.00%

BBIXFBonus BioGroup Ltd.

BBIXFBonus BioGroup Ltd.$0.13+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

INTCIntel

INTCIntel$124.57+0.07%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.02-0.00%

Questions About DTCFF

What is the current price of Defence Therapeutics?

Defence Therapeutics is trading at $0.39 per share.

What is the 52-week range for Defence Therapeutics?

Over the past 52 weeks, Defence Therapeutics has traded between $0.31 and $0.78.

How much debt does Defence Therapeutics have?

As of the most recent reporting period, Defence Therapeutics reported total debt of CA$1.12M.

How much cash does Defence Therapeutics have on hand?

Defence Therapeutics reported CA$2.12M in cash and cash equivalents in its most recent financial results.

What is Defence Therapeutics’s dividend yield?

Defence Therapeutics does not currently have a dividend yield.

Defence Therapeutics

Defence Therapeutics Financials at a Glance

DTCFF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Defence Therapeutics

DTCFF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Defence Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DTCFF

What is the current price of Defence Therapeutics?

What is the 52-week range for Defence Therapeutics?

How much debt does Defence Therapeutics have?

How much cash does Defence Therapeutics have on hand?

What is Defence Therapeutics’s dividend yield?

Premium Investing Services